

USFDA completes inspection at Lupin's Indore facility

28 January 2019 | News

The inspection was carried out between January 14 and January 25, 2019



United States Food and Drug Administration (USFDA) has completed inspection at Lupin's Pithampur Unit-2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019. The inspection at Pithampur Unit-2 (Indore) closed with 6 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally